Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 1005-1007

  Avettand Fenoel, Véronique ^a,b   Flandre, Philippe ^c   Chaix, Marie Laure ^a,b   Ghosn, Jade ^b,d   Delaugerre, Constance ^a,b   Raffi, François ^e   NgoVan, Philippe ^a   Cohen Codar, Isabelle ^a   Delfraissy, Jean François ^d   Rouzioux, Christine ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d BICÊTRE HOSPITAL   (France)

^e Abbott Rungis ^*

Author keywords

Antiretroviral naive patients; HIV reservoirs; Protease inhibitors

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOCYTE; MAJOR CLINICAL STUDY; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS LOAD; BLOOD CELL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY;

ANTI-HIV AGENTS; BLOOD CELLS; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; PYRIMIDINONES; RITONAVIR; VIRAL LOAD;

EID: 77953718387     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq084     Document Type: Article

References (11)

1. Delfraissy JF, Flandre P, Delaugerre C et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22: 385-93.
2. Ghosn J, Flandre P, Cohen-Codar I et al. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med 2010; 11: 137-42.
3. Havlir DV, Strain MC, Clerici M et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77: 11212-9.
4. Hatzakis AE, Touloumi G, Pantazis N et al. Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 2004; 18: 2261-7.
5. Hoen B, Cooper DA, Lampe FC et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007; 45: 381-90.
6. Viard JP, Burgard M, Hubert JB et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18: 45-9.
7. Morand-Joubert L, Marcellin F, Launay O et al. Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081). J Acquir Immune Defic Syndr 2005; 38: 268-76.
8. Avettand-Fenoel V, Chaix ML, Blanche S et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81: 217-23.
9. Avettand-Fenoel V, Prazuck T, Hocqueloux L et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 2008; 22: 1880-2.
10. Flandre P, Delaugerre C, Ghosn J et al. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK trial randomized to ritonavir-boosted lopinavir alone. Antivir Ther 2009; 14: 93-7.
11. Ngo-Giang-Huong N, Deveau C, Da Silva I et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15: 665-73.